Syndax Pharmaceuticals (SNDX) Research & Development (2016 - 2020)
Historic Research & Development for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to $15.5 million.
- Syndax Pharmaceuticals' Research & Development rose 6335.51% to $15.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $50.4 million, marking a year-over-year increase of 1730.71%. This contributed to the annual value of $241.6 million for FY2024, which is 4822.06% up from last year.
- Syndax Pharmaceuticals' Research & Development amounted to $15.5 million in Q4 2020, which was up 6335.51% from $14.4 million recorded in Q3 2020.
- Syndax Pharmaceuticals' 5-year Research & Development high stood at $16.6 million for Q4 2017, and its period low was $4.8 million during Q1 2016.
- Its 5-year average for Research & Development is $11.7 million, with a median of $11.7 million in 2017.
- In the last 5 years, Syndax Pharmaceuticals' Research & Development soared by 31354.45% in 2016 and then tumbled by 3994.06% in 2019.
- Quarter analysis of 5 years shows Syndax Pharmaceuticals' Research & Development stood at $8.5 million in 2016, then skyrocketed by 95.88% to $16.6 million in 2017, then decreased by 4.69% to $15.8 million in 2018, then tumbled by 39.94% to $9.5 million in 2019, then soared by 63.36% to $15.5 million in 2020.
- Its last three reported values are $15.5 million in Q4 2020, $14.4 million for Q3 2020, and $10.9 million during Q2 2020.